Key statistics dashboard for None (BMRA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications.
Stock Data
| Price | $2.37 |
| Market Cap | $7M |
| Beta | 0.20 |
Valuation Multiples
| P/E Ratio | -1.89 |
| Price / Book | 2.77 |
| P/S | 1.65 |
| P/FCF | -2.12 |
Profitability
| Gross Margin | 8.09% |
| EBIT Margin | -93.15% |
| EBITDA Margin | -83.69% |
| Operating Margin | -119.54% |
| Net Margin | -84.79% |
Financial Health
| Current Ratio | 1.62 |
| Quick Ratio | 0.93 |
| Cash Ratio | 0.53 |
| Debt / Equity | 0.72 |
| Debt / Assets | 27.86% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -11.56 |
Per-Share Data
| Revenue per share | 1.45 |
| Book Value per share | 0.86 |
| Cash per share | 0.43 |
| FCF per share | -1.13 |
| Tangible Book Value per share | 0.79 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |